Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals.
Type 2 diabetes mellitus (T2DM) is a major public health problem in China. Diagnostic markers are urgently needed to identify individuals at risk of developing T2DM and encourage them to adapt to a healthier life style. Circulating miRNAs present important sources of noninvasive biomarkers of various diseases. Recently, a novel plasma microRNA signature was identified in T2DM. Here, we evaluated the T2DM-related miRNA signature in plasma of three study groups: normal (fasting glucose (FG), 4.8-5.2 mmol/L), T2DM-susceptible (FG, 6.1-6.9 mmol/L), and T2DM individuals (FG, ≥ 7.0 mmol/L) and tested the feasibility of using circulating miRNAs to identify individuals at risk of developing T2DM. Among the 5 miRNAs included in the signature, miR-29b and miR-28-3p are not detectable. miR-15a and miR-223 have comparable expression levels among three groups. Notably, miR-126 is the only miRNA that showed significantly reduced expression in susceptible individuals and T2DM patients compared to normal individuals, suggesting that miR-126 in circulation may serve as a potential biomarker for early identification of susceptible individuals to T2DM.
Department of Laboratory Medicine, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong 518054, China.
Tao
T
Zhang
Department of Laboratory Medicine, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong 518054, China.
Chunfang
C
Lv
Department of Laboratory Medicine, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong 518054, China.
Liling
L
Li
Department of Control and Prevention for Chronic Non-Communicable Diseases, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong 518054, China.
Sihan
S
Chen
Biomedical Research Institute, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China.
Shenglin
S
Liu
Department of Control and Prevention for Chronic Non-Communicable Diseases, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong 518054, China.
Changyi
C
Wang
Biomedical Research Institute, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China ; Shenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China ; Shenzhen Key Discipline of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China ; Department of Social and Preventive Medicine, School of Public Health and Health Professions, The State University of New York, Buffalo, NY 14214, USA ; Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Bing
B
Su
D000368:Aged; D015415:Biomarkers / Q000097:blood*; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D042241:Early Diagnosis; D005260:Female; D020869:Gene Expression Profiling; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged
D015415:Biomarkers; C527111:MIRN126 microRNA, human; D035683:MicroRNAs